We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Konkan Gyanpeeth Rahul Dharkar College of Pharmacy & Research Institute, Karjat, Maharashtra, India
Transdermal drug delivery systems (TDDS) have emerged as a sophisticated, non-invasive alternative to oral and parenteral administration, offering benefits such as bypassed first-pass metabolism and enhanced patient compliance. While conventional patches—including reservoir and matrix designs—have successfully delivered low-molecular-weight lipophilic drugs, their efficacy is inherently restricted by the "brick-and-mortar" barrier of the stratum corneum. This review examines the paradigm shift from passive diffusion to active and advanced delivery technologies. We analyze the mechanisms of microneedle-based systems, which create transient microchannels for the painless delivery of macromolecules, and nanotechnology-based carriers that improve the solubility and stability of poorly permeable agents. Furthermore, we discuss the role of vesicular systems like transferosomes and ethosomes in enhancing lipid fluidization, alongside hydrogel-based platforms that provide a hydrated environment for sustained release. A significant focus is placed on the emergence of smart transdermal patches. By integrating sensors and stimuli-responsive materials, these systems enable real-time physiological monitoring and on-demand drug release triggered by internal or external factors such as pH, temperature, or light. As these technologies converge, they pave the way for personalized medicine, offering highly precise and patient-centric therapeutic solutions for chronic disease management.
Transdermal drug delivery systems (TDDS) have emerged as an innovative and patient-friendly approach for administering therapeutic agents through the skin into systemic circulation. Traditionally, drug delivery has relied on oral and parenteral routes; however, these methods present several limitations, including poor bioavailability, gastrointestinal degradation, fluctuating plasma drug levels, and issues related to patient compliance (1). TDDS addresses many of these challenges by offering a non-invasive alternative that ensures controlled and sustained drug release while bypassing hepatic first-pass metabolism. The skin, being the largest organ of the human body, provides an accessible route for drug administration. However, its outermost layer, the stratum corneum, serves as a highly efficient barrier that restricts the penetration of most drugs. As a result, only molecules with specific physicochemical properties such as low molecular weight, adequate lipophilicity, and high potency are suitable for conventional transdermal delivery (2).
Despite these limitations, early transdermal systems have been successfully developed and marketed for drugs like nitroglycerin, fentanyl, nicotine, and hormonal therapies. These systems typically utilize designs such as reservoir, matrix, and drug-in-adhesive patches to deliver drugs at a controlled rate over an extended period (3). Over the past few decades, significant research efforts have been directed toward overcoming the barrier function of the skin and expanding the range of drugs that can be delivered transdermally. Various enhancement strategies have been developed, broadly categorized into passive and active approaches. Passive methods include the use of chemical penetration enhancers, prodrugs, and vesicular systems such as liposomes and ethosomes, which improve drug solubility and permeability. In contrast, active techniques such as iontophoresis, sonophoresis, and electroporation employ external energy sources to temporarily disrupt the skin barrier and facilitate drug transport (4). More recently, the integration of advanced technologies has revolutionized TDDS, leading to the development of novel systems such as microneedles, nanocarriers, and hydrogel-based platforms. Microneedle arrays, for instance, create microscopic channels in the skin, enabling the delivery of large biomolecules, including peptides, proteins, and vaccines, with minimal pain and improved efficacy. Similarly, nanotechnology-based systems enhance drug stability, targeting, and controlled release, thereby improving therapeutic outcomes (5).
A major breakthrough in this field is the emergence of smart transdermal patches, which incorporate sensors, microprocessors, and stimuli-responsive materials. These advanced systems can monitor physiological parameters such as glucose levels, pH, or temperature and adjust drug release accordingly, enabling real-time, feedback-controlled therapy. Such innovations align with the growing emphasis on personalized medicine and precision healthcare (6). In conclusion, the evolution of transdermal drug delivery systems from conventional patches to sophisticated smart platforms reflects continuous advancements in pharmaceutical sciences and biomedical engineering. These systems not only improve therapeutic efficacy and safety but also enhance patient convenience and compliance. As research progresses, TDDS is expected to play an increasingly important role in modern drug delivery, offering new possibilities for the treatment of a wide range of diseases (7).
Structure of Skin and Drug Permeation
The skin is a complex, multilayered organ that acts as a protective barrier while also serving as a route for transdermal drug delivery. It consists of three primary layers: the epidermis, dermis, and hypodermis. The epidermis is the outermost layer and contains the stratum corneum, which is the principal barrier to drug permeation (8). This layer is composed of dead, keratinized cells (corneocytes) embedded in a lipid matrix, often described as a “brick-and-mortar” structure. Beneath the epidermis lies the dermis, a vascularized connective tissue layer containing blood vessels, nerves, and lymphatics. Once a drug penetrates the epidermis and reaches the dermis, it can be absorbed into systemic circulation (9). The hypodermis, composed mainly of adipose tissue, provides structural support and insulation. Drug permeation through the skin occurs via three main pathways: transcellular (through cells), intercellular (between cells), and appendageal (via hair follicles and sweat glands). Among these, the intercellular route is the most common due to the lipid-rich environment of the stratum corneum. The efficiency of drug permeation depends on factors such as molecular size, lipophilicity, concentration gradient, and skin hydration (10). Understanding these mechanisms is essential for designing effective transdermal drug delivery systems.
Figure 1: Multilayered Skin Structure and Pathways for Transdermal Drug Permeation
(a) Cross-Sectional Overview of the Skin: This panel illustrates the three primary anatomical layers: the non-vascularized epidermis, the vascularized dermis (containing blood vessels, lymphatics, and nerves), and the underlying hypodermis (adipose tissue), which serves as the entry point into systemic circulation.
(b) Enlarged View of the Epidermis and Stratum Corneum: This section highlights the stratum corneum (SC), the principal rate-limiting barrier to permeation. The inset depicts the magnified “brick-and-mortar” configuration, where corneocytes (the bricks) are embedded within a complex lipid matrix (the mortar).
(c) Major Drug Permeation Pathways: These schematic details the specific routes molecules take to pass through the SC barrier and reach the dermis for absorption:
(d) Critical Factors Influencing Permeation: A summary diagram highlighting the key physical and chemical parameters that determine the efficiency of transdermal drug delivery. This includes the physicochemical properties of the drug itself (molecular size and lipophilicity), formulation-specific variables (concentration gradient and hydration level), and biological variables (barrier integrity) (11).
Conventional Transdermal Patches
Conventional transdermal patches represent the earliest and most widely used form of transdermal drug delivery systems (TDDS). These patches are designed to deliver drugs across the skin at a controlled rate into systemic circulation over an extended period. The concept of transdermal delivery gained significant attention due to its ability to overcome limitations associated with oral and parenteral routes, such as gastrointestinal degradation, first-pass metabolism, and fluctuating plasma drug levels (12).
The first successful transdermal patch was introduced for the delivery of scopolamine for motion sickness, followed by patches containing drugs like nitroglycerin, nicotine, fentanyl, and estrogen. These systems are particularly useful for chronic conditions requiring sustained drug release and consistent therapeutic levels (13).
Fundamental Architecture of Transdermal Delivery Systems
The design and clinical efficacy of a transdermal patch are predicated on a multi-laminate architecture, where each component is engineered to maintain structural integrity while facilitating controlled drug release. A standard transdermal system is comprised of the following functional layers:
Classification of Conventional Transdermal Therapeutic Systems (TTS)
The architecture of transdermal patches is categorized based on the physical state of the drug and the mechanism governing its release. These systems are broadly classified into four distinct technological generations:
Figure 2: Classification of Conventional Transdermal Therapeutic Systems (TTS)
Mechanism of Drug Release from Transdermal Patches
Drug release from conventional transdermal patches occurs primarily through diffusion, which is considered the principal mechanism responsible for the movement of drug molecules from the patch into systemic circulation. In transdermal drug delivery systems, the drug is incorporated into a polymeric matrix or reservoir and is gradually released at a controlled rate after application to the skin. The efficiency of drug delivery depends on the physicochemical properties of the drug, the formulation characteristics of the patch, and the barrier properties of the skin (21).
Figure 2: Mechanism of Drug Release from Transdermal Patches
The first step in the mechanism involves drug release from the patch formulation. After the transdermal patch is applied to the skin surface, the drug is liberated from the polymeric matrix or reservoir system. The release process is generally governed by concentration gradients, which facilitate the movement of drug molecules from regions of higher concentration within the patch to lower concentration at the skin surface.
The second step is penetration through the stratum corneum, which represents the outermost layer of the skin and serves as the primary rate-limiting barrier for transdermal drug absorption. Drug molecules must overcome this highly organized lipid-rich barrier before entering deeper skin layers. Successful penetration through the stratum corneum is essential for effective transdermal delivery and is often enhanced by the use of chemical permeation enhancers or specialized formulation strategies (22).
Following penetration, the drug undergoes diffusion through the epidermis and dermis. In this stage, drug molecules migrate through the viable layers of the skin via intercellular and intracellular pathways. The epidermis and dermis contain aqueous and lipid domains that facilitate further transport of the drug toward the underlying blood vessels. The diffusion process is influenced by the physicochemical characteristics of the drug, including molecular size, lipophilicity, and solubility.
The final step involves absorption into systemic circulation. Once the drug reaches the dermal capillary network, it is absorbed into the bloodstream and distributed throughout the body to exert its therapeutic effect. This mechanism allows transdermal patches to provide sustained and controlled drug delivery while avoiding first-pass hepatic metabolism and reducing fluctuations in plasma drug concentration (23).
The rate of drug release from transdermal patches is influenced by several important factors. These include drug concentration within the patch, which determines the concentration gradient driving diffusion; the diffusion coefficient of the drug, which reflects the ability of drug molecules to move through the skin layers; the thickness of the skin, which affects the diffusion pathway length; and the presence of permeation enhancers, which can temporarily alter the structure of the stratum corneum and improve drug permeation across the skin barrier (24).
Conventional transdermal patches have played a crucial role in the advancement of drug delivery systems by providing a non-invasive, controlled, and patient-friendly alternative to traditional routes of administration. Their well-established design, ease of use, and proven efficacy have made them an integral part of modern therapeutics. However, limitations related to skin permeability and drug selection have restricted their broader application. These challenges have paved the way for the development of advanced transdermal technologies, including microneedles, nanocarriers, and smart patches, which aim to enhance drug delivery efficiency and expand the range of deliverable drugs. Nevertheless, conventional patches continue to serve as the foundation for these innovations and remain widely used in clinical practice (25).
Strategies to Enhance Transdermal Drug Delivery
Enhancing transdermal drug delivery is essential due to the highly protective nature of the stratum corneum, which restricts the penetration of most therapeutic agents. To overcome this barrier and expand the range of drugs suitable for transdermal administration, various strategies have been developed. These approaches are broadly classified into passive and active enhancement techniques, each targeting improved permeability and drug transport across the skin (26).
Passive Enhancement Techniques
Passive enhancement techniques are widely used in transdermal drug delivery systems to improve drug permeation across the skin without the use of external physical energy. These strategies mainly focus on modifying the formulation properties or physicochemical characteristics of the drug to facilitate diffusion through the stratum corneum. One of the most commonly used methods involves chemical penetration enhancers, which temporarily disrupt the lipid arrangement of the stratum corneum and increase skin permeability. Common enhancers such as alcohols, fatty acids, surfactants, and terpenes improve drug solubility and promote partitioning of drug molecules into the skin. However, the selection of suitable enhancers is important because excessive disruption of the skin barrier may result in irritation or skin damage (27). Another important passive strategy is the prodrug approach, where the parent drug is chemically modified into a more lipophilic derivative to enhance its ability to cross the skin barrier. Once absorbed through the skin, the prodrug is converted back into its active therapeutic form within the body, thereby improving transdermal absorption of drugs with poor permeability.
Advanced passive delivery systems such as vesicular systems and nanotechnology-based carriers have significantly improved the efficiency of transdermal drug delivery. Vesicular carriers including liposomes, niosomes, transfersomes, and ethosomes encapsulate drug molecules and enhance their penetration by interacting with skin lipids. These systems also improve drug stability and provide controlled or sustained drug release. In addition, nanotechnology-based carriers such as nanoparticles, nanoemulsions, and solid lipid nanoparticles increase drug surface area, enhance solubility, and improve skin interaction, thereby promoting more effective drug permeation. These nanocarriers are especially useful for poorly soluble drugs and may also provide targeted delivery and prolonged therapeutic action, making them highly promising tools in modern transdermal therapeutics (28).
Active Enhancement Techniques
Active enhancement techniques employ external physical energy or mechanical methods to temporarily disrupt the skin barrier and facilitate drug transport across the stratum corneum. One widely used approach is iontophoresis, which utilizes a low electrical current to drive charged drug molecules through the skin. This technique is particularly effective for hydrophilic drugs and allows controlled delivery by regulating the electrical current. Another important method is sonophoresis, also known as ultrasound-assisted drug delivery, in which ultrasound waves disrupt the lipid structure of the skin and enhance drug diffusion. Sonophoresis improves the permeability of both small and large molecules and has gained considerable attention as a non-invasive transdermal enhancement technique (29).
Another advanced active strategy is electroporation, where short high-voltage electrical pulses create temporary pores in the skin, facilitating the transport of large therapeutic molecules such as peptides and proteins. This method significantly enhances skin permeability and expands the range of drugs that can be delivered transdermally. In recent years, microneedles have emerged as one of the most promising active enhancement systems. Microneedles create microscopic channels in the skin without reaching nerve endings, making the procedure minimally invasive and painless. These microchannels enable efficient delivery of macromolecules, vaccines, biologics, and other therapeutic agents that are otherwise difficult to administer through conventional transdermal patches (30).
Combination Approaches
Recent advancements in transdermal drug delivery have focused on the development of combination approaches that integrate multiple enhancement strategies to achieve superior therapeutic outcomes. These hybrid systems are designed to overcome the limitations associated with individual enhancement techniques and improve overall drug permeation across the skin barrier. For example, combining chemical penetration enhancers with iontophoresis can simultaneously increase skin permeability and facilitate active transport of drug molecules. Similarly, the integration of microneedles with vesicular systems or nanoparticles can significantly enhance the delivery efficiency of both small and large therapeutic agents.
Strategies to enhance transdermal drug delivery have evolved from simple chemical modifications to advanced physical and nanotechnological approaches. Passive methods improve drug compatibility with the skin, while active techniques overcome the barrier function more effectively. The integration of these strategies has expanded the scope of transdermal delivery, enabling the administration of a wider range of drugs, including macromolecules. Continued research in this field is expected to further optimize these techniques and support the development of more efficient and patient-friendly (31).
Novel and Advanced Transdermal Systems
The limitations of conventional transdermal drug delivery systems—primarily poor permeability and restriction to small, lipophilic drugs—have led to the development of novel and advanced transdermal systems. These modern approaches integrate material science, nanotechnology, and biomedical engineering to enhance drug transport across the skin and expand the range of deliverable therapeutics, including macromolecules such as proteins, peptides, and vaccines (32).
Figure 3. Advanced Transdermal Drug Delivery System
Microneedle-based systems are among the most promising advancements in transdermal drug delivery. These micron-scale needles (25–1000 µm) create temporary microchannels in the skin, bypassing the stratum corneum without reaching nerve endings, thereby enabling painless drug administration. Microneedles improve bioavailability, allow precise dosing, and are especially useful for delivering vaccines, peptides, proteins, and biologics.
Microneedles are classified into several types, including solid microneedles for skin pretreatment, coated microneedles with drug-coated surfaces, dissolving microneedles made from biodegradable polymers, and hollow microneedles used for direct delivery of liquid formulations. These systems significantly enhance transdermal permeation and therapeutic efficiency (33).
Nanotechnology-based systems have revolutionized transdermal drug delivery by improving drug solubility, stability, targeting efficiency, and skin permeation. Nanocarriers operate at the nanoscale and interact effectively with skin structures, making them particularly beneficial for poorly soluble and unstable drugs.
Common nanocarriers include polymeric nanoparticles, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and nanoemulsions. These systems enhance drug permeation by increasing surface area, improving drug partitioning into the skin, and enabling controlled drug release, thereby improving therapeutic outcomes (34).
Vesicular drug delivery systems are lipid-based carriers that encapsulate drugs and facilitate their transport across the skin barrier. These systems improve drug stability, enhance penetration through interaction with skin lipids, and provide controlled drug release.
Important vesicular carriers include liposomes, which improve drug solubility; transfersomes, which are ultra-deformable vesicles capable of penetrating intercellular spaces; and ethosomes, which contain high ethanol concentrations that enhance lipid fluidization and skin permeability. These systems significantly improve transdermal drug diffusion (35).
Hydrogels are three-dimensional polymeric networks capable of retaining large amounts of water, thereby creating a hydrated environment that enhances drug diffusion and skin permeability. They possess excellent biocompatibility, flexibility, and are capable of providing controlled and sustained drug release.
Hydrogel-based systems also reduce skin irritation and improve patient comfort. In recent years, hydrogels have increasingly been combined with microneedles and nanocarriers to develop hybrid systems with improved drug delivery efficiency and enhanced therapeutic performance (36).
Stimuli-responsive or smart transdermal systems release drugs in response to specific internal or external triggers such as temperature, pH, light, enzymes, or magnetic fields. These systems provide site-specific and controlled drug delivery, thereby improving therapeutic efficacy and minimizing side effects.
The incorporation of smart materials into transdermal systems has expanded the potential for precision medicine and personalized therapy. Their ability to achieve controlled, on-demand drug release makes them highly promising for future advanced transdermal drug delivery applications (37).
CONCLUSION
The evolution of transdermal drug delivery systems (TDDS) marks a significant shift from simple, passive diffusion patches to sophisticated, multi-functional platforms. Conventional patches, while foundational, are limited by the formidable barrier of the stratum corneum and the specific physicochemical requirements of drug molecules. However, the integration of microneedles, nanotechnology, and vesicular carriers has successfully bypassed these constraints, enabling the painless and efficient delivery of high-molecular-weight biologics, vaccines, and poorly soluble drugs. These advancements ensure controlled release, improved bioavailability, and enhanced patient compliance by offering non-invasive alternatives to oral and parenteral routes
FUTURE PERSPECTIVES
The future of transdermal therapy lies in the refinement of "Smart Patches" and hybrid systems that align with the goals of personalized and precision medicine. Key areas for future development include:
Overall, as research progresses in materials science and biomedical engineering, advanced TDDS are poised to play a central role in chronic disease management and the global delivery of complex biotherapeutics.
REFERENCE
Manish Gharat, Vaishnavi Ghare, Akanksha Ghatvisave, Sneha Gholap, Kiran Ghonge, Vaibhav Gabhale, Evolution of Transdermal Drug Delivery: From Conventional Polymeric Patches to Stimuli-Responsive Smart Platforms, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 7815-7828. https://doi.org/10.5281/zenodo.20441113
10.5281/zenodo.20441113